Category Archives: AZBio News
A New Method for Healing Hearts
A UA surgeon is exploring how amniotic tissue, with its anti-inflammatory and anti-scarring properties, may help prevent complications after heart surgery.Continue reading
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Glioma
Insys Therapeutics, Inc., a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) for the treatment of glioma, which comprises approximately eighty percent of all malignant brain tumors. The ODD includes pontine glioma (PG), a devastating form of primary brainstem glioma.Continue reading
$1.8M grant supports UA Cancer Center’s cancer biology program in Tucson
TUCSON, Ariz. – The National Cancer Institute has awarded the University of Arizona Cancer Center a $1.8 million grant to continue training cancer researchers for the future.Continue reading
Understanding Prop 303 – The Right to Try
This November, Arizona voters will have an opportunity to decide if Proposition 303 called “The Right to Try” should become law in Arizona. It is important to understand what this proposed law does and does not do.Continue reading
Critical Path Institute Receives Second Grant for Advancing Tuberculosis Treatments
New multi-year grant from the the Bill & Melinda Gates Foundation continues work to study pressing public health crisis
ASU Scientists to speak at BIO Pacific Rim Summit on Industrial Biotechnology
Mayo grant will advance ASU’s development of device to aid diabetics
An award of $65,000 from Mayo Clinic in Arizona will help Arizona State University bioengineer Jeffrey La Belle continue development of a tear-based glucose meter designed to help people living with diabetes monitor their health.
U.S. Food and Drug Administration Continues Funding Critical Path Institute
New multi-year grant furthers non-profit organization’s work to accelerate the drug development process